Microparticles for Vaccine Delivery

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-0-323-39981-4.00014-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Needle-Free Dermal Delivery of a Diphtheria Toxin CRM197 Mutant on Potassium-Doped Hydroxyapatite Microparticles

  2015cited by this paper
• Alginate microparticles loaded with lipopolysaccharide subunit antigen for mucosal vaccination against Klebsiella pneumoniae.

  2015cited by this paper
• Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities.

  2015cited by this paper
• Recombinant L7/L12 protein entrapping PLGA (poly lactide-co-glycolide) micro particles protect BALB/c mice against the virulent B. abortus 544 infection.

  2015cited by this paper
• Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response.

  2015cited by this paper
• Dendritic cell-based vaccine research against cancer

  2015cited by this paper
• Efficient delivery of antigen to DCs using yeast-derived microparticles

  2015cited by this paper
• Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.

  2015cited by this paper
• Biodegradable poly-l-lactide based microparticles as controlled release delivery system for filarial vaccine candidate antigens.

  2015cited by this paper
• Preparation and Characterization of Novel PBAE/PLGA Polymer Blend Microparticles for DNA Vaccine Delivery

  2014cited by this paper
• Antigen Delivery by Lipid-Enveloped PLGA Microparticle Vaccines Mediated by in Situ Vesicle Shedding

  2014cited by this paper
• Combination of doxorubicin-based chemotherapy and polyethylenimine/p53 gene therapy for the treatment of lung cancer using porous PLGA microparticles.

  2014cited by this paper
• Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.

  2014cited by this paper
• Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan.

  2014cited by this paper
• A Therapeutic Microparticle-Based Tumor Lysate Vaccine Reduces Spontaneous Metastases in Murine Breast Cancer

  2014cited by this paper
• Cell-free Tumor Microparticle Vaccines Stimulate Dendritic Cells via cGAS/STING Signaling

  2014cited by this paper
• Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.

  2014cited by this paper
• Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles.

  2013cited by this paper
• Vaccine design: emerging concepts and renewed optimism.

  2013cited by this paper
• Mucosal application of cationic poly(D,L-lactide-co-glycolide) microparticles as carriers of DNA vaccine and adjuvants to protect chickens against infectious bursal disease.

  2013cited by this paper
• Vaccine delivery carriers: insights and future perspectives.

  2013cited by this paper
• Hydrolytic cationic ester microparticles for highly efficient DNA vaccine delivery.

  2013cited by this paper
• Encapsulation of chimeric protein rSAG1/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against Toxoplasma gondii in mice.

  2013cited by this paper
• Cationic microparticle [poly(d,l‐lactide‐co‐glycolide)]‐coated DNA vaccination induces a long‐term immune response against foot and mouth disease in guinea pigs

  2012cited by this paper
• calcium Alginate microparticles As a Non-condensing DNA Delivery and transfection System for macrophages

  2012cited by this paper
• Formulation and evaluation of a particulate oral breast cancer vaccine.

  2012cited by this paper
• Formulation and evaluation of oral microparticulate ovarian cancer vaccines.

  2012cited by this paper
• Vaccines: From Empirical Development to Rational Design

  2012cited by this paper
• Delivery of chemotherapeutic drugs in tumour cell-derived microparticles

  2012cited by this paper
• Oral microparticulate vaccine for melanoma using M-cell targeting

  2012cited by this paper
• A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

  2011cited by this paper
• Adjuvant properties of a biocompatible thermo-responsive polymer of N-isopropylacrylamide in autoimmunity and arthritis

  2011cited by this paper
• Recent trends in vaccine delivery systems: A review

  2011cited by this paper
• MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma.

  2011cited by this paper
• Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.

  2011cited by this paper
• Polymeric particles in vaccine delivery.

  2010cited by this paper
• Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers

  2010cited by this paper
• Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention.

  2010cited by this paper
• Evaluation of Mucoadhesive PLGA Microparticles for Nasal Immunization

  2010cited by this paper
• Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses

  2010cited by this paper
• Scaffolding to build a rational vaccine design strategy

  2010cited by this paper
• Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses.

  2009cited by this paper
• Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.

  2008cited by this paper
• Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.

  2008cited by this paper
• Nanoscale double emulsions stabilized by single-component block copolypeptides

  2008cited by this paper
• A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles

  2007cited by this paper
• Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response.

  2007cited by this paper
• Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.

  2006cited by this paper
• Microparticle-based technologies for vaccines.

  2006cited by this paper
• Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.

  2005cited by this paper
• CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine

  2005cited by this paper
• Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles.

  2005cited by this paper
• Drug-conjugated monoclonal antibodies for the treatment of cancer.

  2005cited by this paper
• Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1

  2004cited by this paper
• Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application.

  2004cited by this paper
• Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.

  2004cited by this paper
• Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines

  2004cited by this paper
• Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects

  2004cited by this paper
• Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.

  2004cited by this paper
• Cationic microparticles are a potent delivery system for a HCV DNA vaccine.

  2004cited by this paper
• Phagocytosis and Phagosomal Fate of Surface-Modified Microparticles in Dendritic Cells and Macrophages

  2003cited by this paper
• Microparticles as vaccine adjuvants and delivery systems

  2003cited by this paper
• The Effect of CTAB Concentration in Cationic PLG Microparticles on DNA Adsorption and in Vivo Performance

  2003cited by this paper
• A minimal human immunostimulatory CpG motif that potently induces IFN‐γ and IFN‐α production

  2003cited by this paper
• Gene Vaccines

  2003cited by this paper
• Cancer vaccines: between the idea and the reality

  2003cited by this paper
• A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.

  2002cited by this paper
• Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo.

  2002cited by this paper
• Analysis of Poly(D,L-Lactic-Co-Glycolic Acid) Nanosphere Uptake by Human Dendritic Cells and Macrophages In Vitro

  2002cited by this paper
• The Preparation, Characterization, and Evaluation of Cationic Microparticles for DNA Vaccine Delivery

  2001cited by this paper
• Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA

  2001cited by this paper
• Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

  2001cited by this paper
• Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

  2000cited by this paper
• Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. I. In vitro characterization.

  2000cited by this paper
• Development of a preventive vaccine for Ebola virus infection in primates

  2000cited by this paper
• Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

  2000cited by this paper
• Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.

  2000cited by this paper
• The Teeth of the Tyrannosaurs

  1999cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles.

  1998cited by this paper
• Microparticles and polymers for the mucosal delivery of vaccines.

  1998cited by this paper
• Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.

  1995cited by this paper
• Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

  1995cited by this paper
• Immunization of human HIV‐seronegative volunteers with recombinant p17/p24: Ty virus‐like particles elicits HIV‐1 p24‐specific cellular and humoral immune responses

  1993cited by this paper
• Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres

  1987cited by this paper

• Characterization and in vivo assay of chitosan alginate microencapsulation to deliver the combination of HBcAg and HBsAg as a hepatitis B oral vaccine candidate

  2022cites this paper
• Functional Interactions Between Bottom‐Up Synthetic Cells and Living Matter for Biomedical Applications

  2021cites this paper